YM155

• CAT Number: I004872
• CAS Number: 781661-94-7
• Molecular Formula: C₂₀H₁₉BrN₄O₃
• Molecular Weight: 443.29
• Purity: ≥95%
• Target: IAP
• Solubility: DMSO ≥85mg/mL Water ≥85mg/mL Ethanol ≥20mg/mL
• Storage: 3 years -20C powder
• IC50: 0.54 nM
• InChI: InChI=1S/C20H19N4O3.BrH/c1-13-23(9-10-27-2)17-18(24(13)12-14-11-21-7-8-22-14)20(26)16-6-4-3-5-15(16)19(17)25;/h3-8,11H,9-10,12H2,1-2H3;1H/q+1;/p-1
• InChIKey: QBIYUDDJPRGKNJ-UHFFFAOYSA-M
• SMILES: CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

YM155 (CAT: I004872) is a synthetic small molecule that has gained attention for its potential as an anticancer agent. It belongs to the class of survivin inhibitors and exhibits pharmacological activities against various types of cancer. YM155 works by targeting and suppressing the expression of survivin, a protein that promotes cell survival and is often overexpressed in cancer cells. By inhibiting survivin, YM155 induces apoptosis, inhibits cell proliferation, and sensitizes cancer cells to other anticancer treatments. It has shown promising results in preclinical and clinical studies, particularly in the treatment of advanced solid tumors and hematological malignancies.

Reference

1:A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model. Guo K, Huang P, Xu N, Xu P, Kaku H, Zheng S, Xu A, Matsuura E, Liu C, Kumon H.Oncotarget. 2015 Aug 28;6(25):21137-47. PMID: 26023798 Free PMC Article2:Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. Premkumar DR, Jane EP, Foster KA, Pollack IF.J Pharmacol Exp Ther. 2013 Aug;346(2):201-10. doi: 10.1124/jpet.113.204743. Epub 2013 Jun 5. PMID: 23740602 Free PMC Article3:YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF.Mol Cancer Ther. 2013 Mar;12(3):326-38. doi: 10.1158/1535-7163.MCT-12-0901. Epub 2013 Jan 16. PMID: 23325792 Free PMC Article